Evidence map›Paper›PMID 41488398›Full record

ArticleHuman mutation2026

Developing Del2Phen: A Novel Phenotype Description Tool for Chromosome Deletions.

Eleana Rraku, Tyler D Medina, Conny M A van Ravenswaaij-Arts, Mariska K Slofstra, Morris A Swertz, Trijnie Dijkhuizen, Lennart F Johansson, Aafke Engwerda

Abstract read
In one paragraph

Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eleana RrakuDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.ORCID https://orcid.org/0000-0003-0416-3416
Tyler D MedinaDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.
Conny M A van Ravenswaaij-ArtsDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.
Mariska K SlofstraDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.
Morris A SwertzDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.
Trijnie DijkhuizenDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.
Lennart F JohanssonDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.ORCID https://orcid.org/0000-0002-4914-3737
Aafke EngwerdaDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, umcg.nl.ORCID https://orcid.org/0000-0002-7693-1288

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Information on the health-related consequences of rare chromosome disorders is often limited, posing challenges for both patients and their families. The Chromosome 6 Project aims to bridge this knowledge gap for structural aberrations involving chromosome 6 by providing parents of affected children with information on the expected phenotypes of their child. To achieve this, detailed phenotype and genotype data are collected directly from parents worldwide and supplemented with data from literature reports, resulting thus far in a dataset of over 500 individuals. This comprehensive data pool was used to develop Del2Phen, a software tool introduced in this paper that generates aberration-specific phenotype information for chromosome disorders. Del2Phen identifies individuals with a deletion or duplication similar to that of a new patient (index) and produces a clinical description for the index based on phenotypic features observed in these genotypically similar individuals. Genotypic similarity is determined using existing knowledge on the haploinsufficiency effect of genes and established gene-phenotype relationships. The optimal genotypic similarity parameters for chromosome 6 deletions were evaluated, which led to thorough and reliable clinical descriptions based on sufficiently large groups of individuals with highly similar deletions. Although currently optimised for chromosome 6 deletions, Del2Phen can also be applied to deletions involving other chromosomes and is easily adapted for use on duplications, given sufficient data are available. Del2Phen can already be used to expedite data analysis for chromosome disorders, thus aiding healthcare professionals in delivering appropriate clinical care. Lastly, this tool will be integrated into an interactive website designed for parents of children with a chromosome 6 aberration, providing essential health information in a timely and accessible manner.

Indexed as

Chromosome DeletionChromosome DisordersPhenotypeSoftwareChromosomes, Human, Pair 6Genetic Association StudiesGenotypeHumanschromosome 6Chromosome 6 Projectchromosome disorderparentsphenotype informationtool

Identifiers

PMID41488398
PMCPMC12759035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.